Targeting Attention Orienting to Social Threat to Reduce Social Anxiety in Youth (NCT03932032) | Clinical Trial Compass
CompletedNot Applicable
Targeting Attention Orienting to Social Threat to Reduce Social Anxiety in Youth
United States206 participantsStarted 2019-07-01
Plain-language summary
This two-site study is a test of Attention Bias Modification Treatment (ABMT) among 260 youths ages 10 to 14 years with social anxiety disorder. One-half of participants will receive 8 sessions of computer administered ABMT and the other half of participants will receive 8 sessions of computer administered Neutral Control Task (NCT). The investigators hypothesize that a biomarker of attention to social threat measured using electroencephalography (EEG) and ratings of social anxiety severity will be lower in participants who receive ABMT compared to participants who receive NCT.
Who can participate
Age range
10 Years – 14 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Be between ages 10 and 14 years
* meet DSM5 criteria for a diagnosis of Social Anxiety Disorder
* presence of any coexisting psychiatric diagnoses must be of lesser severity than Social Anxiety Disorder
* have no current psychotropic medication other than a stable dose of stimulant or non-stimulant medication for coexisting ADHD
Exclusion Criteria:
* meet DSM5 criteria for Autism Spectrum Disorder, Intellectual Disability, Bipolar Disorder, Tourette's Disorder, Psychotic Disorders, or Substance Use Disorders
* show high likelihood of hurting self or others
* be a victim of undisclosed abuse requiring investigation/ supervision by the Department of Social Services
* have an uncorrected vision or physical disability that interferes with the ability to click a mouse button rapidly and repeatedly
* have a history of neurological illness, including seizures/epilepsy, or head injury with loss of consciousness \> 5 minutes
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
P1 Amplitude Elicited in the Dot-probe Task
Timeframe: post-intervention (within one week of completing the final treatment session)
2
P1 Amplitude Elicited in the Dot-probe Task
Timeframe: Follow-up (six months after completing the final treatment session)